Pursuant to the Regulation 30 of the SEBI Listing Regulations, Solara Active Pharma Sciences has informed that it enclosed a copy of the Press Release on unaudited Financial Results for the 1st Quarter Ended June 30, 2025. The same will also be made available on the website of the Company https://solara.co.in/investor-relations/investor-update/. The Press Release (along with Earnings Presentation) for the Board Meeting held on July 25, 2025 issued by the Company titled: ‘Solara Q1’26 performance’.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: